Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 4/20 | 0.45 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | PHLPP2 | Q6ZVD8 | 1/20 | 0.39 |
| ▸ | CHRNA2 | Q15822 | 3/20 | 0.34 |
| ▸ | CHRNB4 | P30926 | 3/20 | 0.34 |
| ▸ | CHRNA3 | P32297 | 3/20 | 0.34 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.33 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.32 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.32 |
| ▸ | MERTK | Q12866 | 1/20 | 0.32 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1283230 | 0.77 | LTA4H (0.49) | SMN1; SMN2 | |
| SCHEMBL1284405 | 0.74 | TLR8 (0.47) | CYP1A2SMN1; SMN2 | |
| SCHEMBL1283924 | 0.73 | HSP90AA1 (0.41) | CYP1A2CYP2D6HIF1AHSP90AA1HSP90AB1 | |
| SCHEMBL1283603 | 0.73 | CHRNB2 (0.37) | CHRNB2CHRNA4 | |
| SCHEMBL1283533 | 0.71 | HRH3 (0.43) | — | |
| SCHEMBL5025845 | 0.70 | CHRNB4 (0.49) | CHRNB4CHRNA3CHEK2CHEK1 | |
| SCHEMBL7792043 | 0.69 | KCNA3 (0.41) | CHRNB2CHRNA4CHRNB4CHRNA3P2RY12 | |
| SCHEMBL7796453 | 0.67 | CYP1A2 (0.35) | CHRNB2CHRNA4CYP1A2CYP2C19CHRNB4 | |
| SCHEMBL5027399 | 0.67 | ALDH1A1 (0.45) | CYP1A2CYP2D6CYP2C19SMN1; SMN2HIF1A | |
| SCHEMBL11457361 | 0.66 | CHRNB4 (0.54) | CHRNB4CHRNA3CHEK2CHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120088778-A1 | AZOLE DERIVATIVES AND FUSED BICYCLIC AZOLE DERIVATIVES AS THERAPEUTIC AGENTS | TRANSTECH PHARMA, INC. (US) | 2012-04-12 | — | — | US | disclosed |
| US-20100256119-A1 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | TRANSTECH PHARMA, INC. | 2010-10-07 | — | — | US | disclosed |
| US-7737285-B2 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | TRANSTECH PHARMA, INC. (US) | 2010-06-15 | — | — | US | disclosed |
| US-7714013-B2 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | TRANSTECH PHARMA, INC. (US) | 2010-05-11 | — | — | US | disclosed |
| US-7361678-B2 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | TRANSTECH PHARMA, INC. (US) | 2008-04-22 | — | — | US | disclosed |
| US-20070213347-A1 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | TRANSTECH PHARMA (US) | 2007-09-13 | — | — | US | disclosed |
| US-20070021386-A1 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | TRANSTECH PHARMA (US) | 2007-01-25 | — | — | US | disclosed |
| EP-1482931-A2 | MONO- AND BICYCLIC AZOLE DERIVATIVES THAT INHIBIT THE INTERACTION OF LIGANDS WITH RAGE | Transtech Pharma, Inc. (US) | 2004-12-08 | — | — | EP | disclosed |
| US-20040082542-A1 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | VTV THERAPEUTICS LLC | 2004-04-29 | — | — | US | disclosed |
| WO-2003075921-A2 | MONO- AND BICYCLIC AZOLE DERIVATIVES THAT INHIBIT THE INTERACTION OF LIGANDS WITH RAGE | TRANSTECH PHARMA, INC. (US) | 2003-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256119-A1 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | AGER, S100A4, S100B | CHRNB2 551/4885CHRNA4 611/4885CYP1A2 2413/4885 |
| US-20040082542-A1 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | AGER, S100A4, S100B | CHRNB2 707/4885CHRNA4 591/4885CYP1A2 2380/4885 |
| US-20070021386-A1 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | AGER, S100A4, S100B | CHRNB2 505/4885CHRNA4 544/4885CYP1A2 2396/4885 |
| US-20120088778-A1 | AZOLE DERIVATIVES AND FUSED BICYCLIC AZOLE DERIVATIVES AS THERAPEUTIC AGENTS | AGER, S100A4, S100B | CHRNB2 505/4885CHRNA4 544/4885CYP1A2 2396/4885 |
| US-20070213347-A1 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | AGER, S100A4, S100B | CHRNB2 505/4885CHRNA4 544/4885CYP1A2 2396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.